Oral nonpeptide GLP-1 receptor agonist VCT220 for obesity treatment: a randomized, double-blind, phase II trial

The headline reports on a randomized, double-blind, phase II trial of an oral nonpeptide GLP-1 receptor agonist, VCT220, for the treatment of obesity.

Summarised by a model from nature.com's headline and its own description of the story. We did not read the article, and this is not our reporting — the link above is.

On file here

Every number below is counted from this library's own approved studies — the ones with a page you can open and check. Counts move as papers are filed.

What the headline doesn't tell you

• This story is about a class — GLP-1 and incretin therapies — rather than one compound. We track 14 compounds in it, holding 344 studies between them, 150 in humans.

Counted, not written: each line is a sentence filled in from the study counts above. None of it is a judgement about the story or the compound.